GlassScriptPhysician profile
Kasaundra Ewing
NPI 1770607335
$3,595.72
in general payments reported to CMS, 2019-2025
23 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $725 · 2023: $617 · 2024: $986 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,870.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $486.41 | 2024-2025 | Biktarvy, Yeztugo, Descovy |
| Otsuka America Pharmaceutical, INC. | $337.58 | 2023-2025 | Rexulti |
| Abbvie INC. | $300.65 | 2023-2025 | |
| Novo Nordisk INC | $252.57 | 2022-2025 | Wegovy |
| Eisai INC. | $244.64 | 2025 | |
| Sage Therapeutics, LLC | $201.30 | 2023 | |
| Abbott Laboratories | $140.60 | 2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $135.77 | 2024 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $132.69 | 2024 | Reblozyl |
| Lundbeck LLC | $124.99 | 2022 | |
| Kyowa Kirin, INC. | $124.94 | 2025 | |
| Corium, LLC | $124.93 | 2022 | |
| Astellas Pharma US INC | $124.92 | 2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $123.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.86 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $112.50 | 2025 | Wainua |
| Inspire Medical Systems, INC. | $111.60 | 2024 | Inspire |
| Dexcom, INC. | $89.97 | 2024 | Dexcom G7 Gss (161) |
| Vertex Pharmaceuticals Incorporated | $87.77 | 2025 | |
| Paratek Pharmaceuticals, INC. | $86.78 | 2023 | Nuzyra |
| Spark Therapeutics, INC. | $78.90 | 2022 | |
| Organon LLC | $30.26 | 2022 | |
| Csl Behring | $25.09 | 2024 | Kcentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kasaundra Ewing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.